# Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients

> **NCT00295607** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 138 (actual)

## Conditions studied

- Hepatitis C
- Liver Transplantation

## Interventions

- **DRUG:** Tacrolimus
- **DRUG:** steroids, monoclonal anti-IL2R antibody

## Key facts

- **NCT ID:** NCT00295607
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2013-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295607, "Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00295607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*